 This is an open-label, multi-center, phase II trial using low-dose RAD001 10 mg po on D1,D8,D15 plus P-HDFL chemotherapy cisplatin 35 mgm2 ivd 24 hrs on D1 D8; 5-FU 2,000 mgm2 and leucovorin 300 mgm2 ivd 24 hrs on D1,D8,D15 in chemotherapy-naïve patients with unresectable locally advanced, recurrent or metastatic gastric cancer. The treatment will be repeated every 28 days. The primary end-point is objective response rates evaluated by RECIST criteria, and the secondary end-points are overall survival, progression-free survival and safety profile. Approximately 41 patients will be enrolled in order to obtain the 37 evaluable patients required by Simon two-stage minimax design. All enrolled patients will be subjected to toxicity evaluations, but optionally to the correlative translational study of biomarkers in peripheral blood mononuclear cells. Patients with massive malignant ascites will optionally participate the study of biomarkers in neoplastic cells in ascites. 